MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

Date publication

février 2022

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric

Tous les auteurs :
Boisteau E, Lespagnol A, De Tayrac M, Corre S, Perrot A, Rioux-Leclercq N, Martin-Lannerée S, Artru P, Chalabreysse P, Poureau PG, Doucet L, Coupez D, Bennouna J, Bossard C, Coriat R, Beuvon F, Bauguion L, Leclair F, Chautard R, Lecomte T, Guyetant S, Desgrippes R, Grasset D, Lhostis H, Bouhier-Leporrier K, Bibeau F, Edeline J, Galibert MD, Lièvre A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35189426

Résumé

Low miR-31-3p expression was identified as predictive of anti-EGFR efficacy in RAS-wt mCRC. Primary tumor side was also proposed as a predictive factor of anti-EGFR benefit. This retrospective multicentric study evaluated the predictive role of miR-31-3p in right-sided RAS-wt mCRC patients treated with first-line CT+anti-EGFR or CT+bevacizumab (Beva).

Mots clés

anti-EGFR mAb, bevacizumab, biomarker, colorectal cancer, metastasis, miR-31-3p

Référence

Clin Res Hepatol Gastroenterol. 2022 Feb 18;:101888